Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2025-12-10			5-day change	1st Jan Change
63.38 ^CNY	+0.48%		+3.95%	+38.08%

Dec. 08	Hengrui Medicine's 20 Drugs Included in China's Reimbursement Drug List	MT
Dec. 08	Jiangsu Hengrui Medicine Gets Inclusion in China's Medical Insurance Catalog	MT

JPMorgan Chase & Co's short position in H shares of Jiangsu Hengrui Pharmaceuticals decreases to 2.25% on Nov 3 from 2.95% - HKEX

Published on 11/07/2025 at 06:46 am EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Dec. 08	Hengrui Medicine's 20 Drugs Included in China's Reimbursement Drug List	MT
Dec. 08	Jiangsu Hengrui Medicine Gets Inclusion in China's Medical Insurance Catalog	MT
Dec. 02	Hengrui Medicine Gets Regulatory Acceptance for Anesthetic Marketing Application	MT
Nov. 27	Hengrui Medicine Gets China Approval for Multiple Drug Trials	MT
Nov. 27	Hengrui Medicine Gets Regulatory Nod for Vitiligo Drug Trials	MT
Nov. 25	Hengrui Medicine Gets Clinical Trial Approval for Tumor Monotherapy; Shares Up 3%	MT
Nov. 25	Hengrui Medicine Gets Clinical Trial Approval for Tumor Treatment	MT
Nov. 24	Hengrui Medicine Says Emavusitinib Marketing Application Accepted by Chinese Drug Regulator	MT
Nov. 24	Hengrui Medicine Gets Marketing Approval for Synthetic Vitamin D	MT
Nov. 23	Hengrui Pharmaceuticals Gets Clinical Trial Approval for Skin Disease Treatment	MT
Nov. 21	Certain H Shares of Jiangsu Hengrui Medicine Co., Ltd. are subject to a Lock-Up Agreement Ending on 21-NOV-2025.	CI
Nov. 17	Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Nine Drug Candidates	MT
Nov. 17	Jiangsu Hengrui Medicine Gets China Clinical Trial Nod for Mechanical Ventilation Pain Reliever	MT
Nov. 17	Jiangsu Hengrui Medicine Gets China Clinical Trial Nod for Two Anti-Tumor Drugs	MT
Nov. 14	Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Prostate Cancer Drug	MT
Nov. 09	Hengrui Medicine's Unit Gets Nod to Trial SHR-4610 Injection; Shares Slip 1%	MT
Nov. 09	Jiangsu Hengrui Medicine Gets Regulatory Nod for Anesthetic Drug Trials	MT
Nov. 07	JPMorgan Chase & Co's short position in H shares of Jiangsu Hengrui Pharmaceuticals decreases to 2.25% on Nov 3 from 2.95% - HKEX	RE
Nov. 07	Citigroup's long position in H-shares of Jiangsu Hengrui Pharmaceuticals decreases to 4.67% on Nov 3 from 5.30% - HKEX	RE
Nov. 04	Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual Glp-1/Gip Receptor Agonist Hrs9531	CI
Nov. 03	Jiangsu Hengrui Medicine Gets Approval for Prostate Cancer Drug Trial	MT
Nov. 03	Hengrui Medicine's Blood Disorder Drug Eyed for Priority Review in China	MT
Oct. 28	Shares in China's top drugmaker Hengrui fall as quarterly profit disappoints	RE
Oct. 27	Hengrui Medicine's Attributable Profit Rises 9.5% in Q3	MT
Oct. 27	Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI

Chart Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Duration

Period

Chart Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276: Dynamic Chart

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Employees

20,238

Sector

Pharmaceuticals

Calendar

Apr. 19 - Q1 2026 Earnings Release (Projected)

More about the company